Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ME2 | P23368 | 1/20 | 0.33 |
| ▸ | ME1 | P48163 | 1/20 | 0.33 |
| ▸ | ME3 | Q16798 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104385 | 0.82 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4296583 | 0.80 | TACR1 (0.37) | TEAD1TEAD3CHRM3CHRM1ALDH1A1 | |
| SCHEMBL10053572 | 0.80 | CYP11B1 (0.32) | CHRM3CHRM1ALDH1A1CHRM2LMNA | |
| SCHEMBL23298053 | 0.80 | CYP11B1 (0.32) | CHRM3CHRM1ALDH1A1CHRM2LMNA | |
| SCHEMBL23415499 | 0.80 | CYP11B1 (0.32) | CHRM3CHRM1ALDH1A1CHRM2LMNA | |
| SCHEMBL20595723 | 0.77 | KCNA3 (0.34) | CHRM3CHRM1ALDH1A1CHRM4CHRM5 | |
| SCHEMBL20595800 | 0.77 | KCNA3 (0.34) | CHRM3CHRM1ALDH1A1CHRM4CHRM5 | |
| SCHEMBL28833909 | 0.77 | KCNA3 (0.34) | CHRM3CHRM1ALDH1A1CHRM4CHRM5 | |
| SCHEMBL15412695 | 0.74 | ATM (0.36) | LMNA | |
| SCHEMBL15412693 | 0.74 | ATM (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | TEAD1 2143/4885TEAD3 1323/4885CHRM3 3197/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | TEAD1 2143/4885TEAD3 1323/4885CHRM3 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.